NEW YORK (GenomeWeb News) – BD Diagnostics and Lonza Group today announced an exclusive licensing and collaboration agreement for the commercialization of Lonza's microCompass molecular assay on the BD Max system.
Under the agreement, Lonza has the right to exclusively co-market globally the BD Max system with the complete microCompass product line in selected fields. In a joint statement, BD and Lonza said the microCompass assays will facilitate rapid detection for total bioburden load, sterility testing, Mycoplasma, and other specific organisms.
The microCompass detection system targets ribosomal RNA for the detection of bacteria, yeast, and molds, according to Lonza's website.
The assays on the BD Max system "will provide an automated platform with same day results for quality control testing in the pharmaceutical and personal care products market segments," the companies said.
Based in Basel, Switzerland, Lonza supplies tools, manufacturing services, and ingredients to the life sciences, pharmaceutical, and healthcare industries.
Terms of the deal were not disclosed.